Abstract
Dosage of serum AFP (alpha-fetoprotein) is widely used for HCC screening in patients with chronic liver disease. Virus-related chronic liver disease is the main cause of cirrhosis and HCC in Western and Far Eastern countries, but the relationship between viral etiology and AFP levels in HCC is still unclear. The aim of this study was to verify, in Western patients with post-viral chronic liver disease, the usefulness of AFP dosage for the detection of HCC, and the influence of viral etiology on AFP levels in HCC.
| Original language | English |
|---|---|
| Pages (from-to) | 1654-1658 |
| Number of pages | 5 |
| Journal | Hepato-Gastroenterology |
| Volume | 47 |
| Publication status | Published - 2000 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Biological Markers
- Carcinoma, Hepatocellular
- Chronic Disease
- Female
- Hepatitis B, Chronic
- Hepatitis C, Chronic
- Humans
- Italy
- Liver Diseases
- Liver Neoplasms
- Logistic Models
- Male
- Middle Aged
- Predictive Value of Tests
- Sensitivity and Specificity
- alpha-Fetoproteins
Fingerprint
Dive into the research topics of 'Utility of alpha-fetoprotein (AFP) in the screening of patients with virus-related chronic liver disease: does different viral etiology influence AFP levels in HCC? A study in 350 western patients'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver